Establishment of the Standard Regimen for Non-Small- Cell Lung Cancer in Japan
January 1st 2001Preclinical data suggest that irinotecan (Camptosar, CPT-11), a novel topoisomerase I inhibitor, has exhibited promising activity in the treatment of lung cancer. In a phase II study of non-small-cell lung cancer, irinotecan